Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry

Basit Öğe Kaydı
dc.authorscopusid57202353075
dc.authorscopusid36472957600
dc.authorscopusid24073063700
dc.authorscopusid56433330200
dc.authorscopusid56432961400
dc.authorscopusid57202391627
dc.authorscopusid55777278900
dc.contributor.authorKayıkcioglu M.
dc.contributor.authorBaşaran Ö.
dc.contributor.authorDoğan V.
dc.contributor.authorMert K.U.
dc.contributor.authorMert G.Ö.
dc.contributor.authorÖzdemir İ.H.
dc.contributor.authorRencüzoğulları İ.
dc.date.accessioned2024-01-22T12:22:35Z
dc.date.available2024-01-22T12:22:35Z
dc.date.issued2023
dc.departmentKMÜen_US
dc.description.abstractBACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is a common inherited disease, leading to premature atherosclerotic cardiovascular disease (ASCVD) due to elevated low-density lipoprotein cholesterol (LDL-C) levels. Achieving LDL-C goals is extremely important for preventing the complications of this fatal disease. We evaluated the management of FH patients with ASCVD in cardiology practice. METHODS: We analyzed patients with ASCVD from the nationwide EPHESUS registry, which was conducted in 40 cardiology outpatient clinics, and compared those with and without FH. RESULTS: Of the 1482 consecutively enrolled patients with ASCVD, 618 (41.7%) had FH, among which 455 were categorized as 'Possible FH' and 163 as 'Probable or Definite FH'. Proposed LDL-C goals were not attained in more than 90% of the patients with FH. The proportion of those on statin therapy was 77% for possible and 91% for probable or definite FH, whereas 34.2 % and 59.4% were in use of high-intensity statins, respectively. None of the patients were on PCSK-9 inhibitors, and only 2 used ezetimibe. Adverse media coverage was the most common cause of statin discontinuation (32.5% in 'possible FH' and 45.7% in 'probable/definite FH'). The negative impact of media in the decision to stop lipid lowering therapy (LLT) was increasing with education level. CONCLUSIONS: In real life most of the FH patients with ASCVD are undertreated in cardiology practice regarding statin dosing and combined LLT. Drug discontinuation rates are notably high and are mostly media-related, and side effects very rarely cause cessation of LLT. Urgent measures are needed to increase the awareness of FH among healthcare providers and patients and to develop improved treatment strategies aimed at preventing the complications of FH. © 2023 National Lipid Associationen_US
dc.identifier.doi10.1016/j.jacl.2023.09.013
dc.identifier.endpage742en_US
dc.identifier.issn19332874
dc.identifier.issue6en_US
dc.identifier.pmid38072583en_US
dc.identifier.pmid38072583
dc.identifier.scopus2-s2.0-85179466184
dc.identifier.scopusqualityQ1
dc.identifier.startpage732en_US
dc.identifier.urihttps://doi.org/10.1016/j.jacl.2023.09.013
dc.identifier.urihttps://hdl.handle.net/11492/8055
dc.identifier.volume17en_US
dc.identifier.wosWOS:001165102300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Sceince
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Ltden_US
dc.relation.ispartofJournal of Clinical Lipidologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzkmusnmz
dc.subjectAtherosclerotic cardiovascular diseaseen_US
dc.subjectFamilial hypercholesterolemiaen_US
dc.subjectLDL-cholesterolen_US
dc.subjectLipid-lowering therapyen_US
dc.subjectMedia coverageen_US
dc.subjectSecondary preventionen_US
dc.subjectezetimibeen_US
dc.subjecthigh density lipoprotein cholesterolen_US
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitoren_US
dc.subjectlipiden_US
dc.subjectlow density lipoprotein cholesterolen_US
dc.subjectproprotein convertase 9en_US
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitoren_US
dc.subjecthypocholesterolemic agenten_US
dc.subjectlow density lipoprotein cholesterolen_US
dc.subjectadulten_US
dc.subjectArticleen_US
dc.subjectcardiologisten_US
dc.subjectcardiovascular diseaseen_US
dc.subjectcongenital disorderen_US
dc.subjectcontrolled studyen_US
dc.subjectcoronary atherosclerosisen_US
dc.subjectcross-sectional studyen_US
dc.subjectfamilial hypercholesterolemiaen_US
dc.subjectfemaleen_US
dc.subjectFisher exact testen_US
dc.subjecthealth care personnelen_US
dc.subjecthigh risk patienten_US
dc.subjecthumanen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmiddle ageden_US
dc.subjectoutpatient departmenten_US
dc.subjectphysical examinationen_US
dc.subjectpremature atherosclerosisen_US
dc.subjectquestionnaireen_US
dc.subjectsecondary preventionen_US
dc.subjectatherosclerosisen_US
dc.subjectcardiologyen_US
dc.subjectcomplicationen_US
dc.subjectfamilial hypercholesterolemiaen_US
dc.subjectregisteren_US
dc.subjectsecondary preventionen_US
dc.subjectAnticholesteremic Agentsen_US
dc.subjectAtherosclerosisen_US
dc.subjectCardiologyen_US
dc.subjectCholesterol, LDLen_US
dc.subjectHumansen_US
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitorsen_US
dc.subjectHyperlipoproteinemia Type IIen_US
dc.subjectRegistriesen_US
dc.subjectSecondary Preventionen_US
dc.titleMisperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registryen_US
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu